Comparing the outcomes between TMLI and non-TMLI conditioning regimens for adult high-risk acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a single-center experience. Issue 12 (14th October 2020)

• Record Type: Journal Article
• Authors: Zhao, Xiaoyan; Lu, Xuan; Tang, Liang; Yan, Han; Chen, Wenlan; Shi, Wei; Zhong, Zhaodong; You, Yong; Xia, Linghui; Hu, Yu; Wang, Huafang
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 12(2020)
• Page Start: 2859
• Page End: 2867
• Publication Date: 2020-10-14
• Subjects: Total marrow and lymphoid irradiation -- high-risk acute lymphoblastic leukemia -- hematopoietic stem cell transplantation -- conditioning regimen; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1789621
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: This study aimed to retrospectively evaluate the outcomes of adult patients with high-risk acute lymphoblastic leukemia (ALL) who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) with either total marrow and lymphoid irradiation (TMLI)-containing or non-TMLI conditioning regimen. Seventy adult patients with high-risk ALL who received allo-HSCT were enrolled in this study and divided into two groups based on the conditioning regimen type (TMLI group: n = 29 and non-TMLI group: n = 41). We noted significant statistical differences in the 1-year estimated cumulative incidence of relapse (25% vs. 46.5%, p = 0.018), the 1-year estimated overall survival (73.1% vs. 52.6%, p = 0.033) and disease-free survival (65.2% vs. 48.2%, p = 0.026) but found no considerable difference in transplant-related mortality (12% vs. 13.4%, p = 0.619) between patients in the TMLI and non-TMLI groups. The TMLI-containing regimen is safe and alternative for patients with high-risk ALL undergoing allo-HSCT.